GetTopicDetailResponse(id=d1821023916, topicName=JAK抑制劑Olumiant, introduction=JAK抑制劑Olumiant, content=null, image=null, comments=3, allHits=1116, url=https://h5.medsci.cn/topic?id=10239, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=102573, tagList=[TagDto(tagId=102573, tagName=JAK抑制劑Olumiant)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1993690, encodeId=b19a199369013, content=<a href='/topic/show?id=d1821023916' target=_blank style='color:#2F92EE;'>#JAK抑制劑Olumiant#</a>, objectTitle=JAK抑制劑Olumiant和抗血管生成素-2單抗LY3127804將用于新冠病毒COVID-19患者臨床試驗, objectType=article, longId=192249, objectId=f473192249cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f473192249cd, replyNumber=0, likeNumber=78, createdTime=2020-06-16, rootId=0, userName=ms4657536712156177, userId=20872500216, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f473192249cd, moduleTitle=JAK抑制劑Olumiant和抗血管生成素-2單抗LY3127804將用于新冠病毒COVID-19患者臨床試驗, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f473192249cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993689, encodeId=17ff1993689d2, content=<a href='/topic/show?id=d1821023916' target=_blank style='color:#2F92EE;'>#JAK抑制劑Olumiant#</a>, objectTitle=JAK抑制劑Olumiant聯(lián)合治療特應(yīng)性皮炎的III期試驗達到主要終點, objectType=article, longId=178209, objectId=6ad01e8209da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ad01e8209da, replyNumber=0, likeNumber=94, createdTime=2020-06-05, rootId=0, userName=ms4657536712156177, userId=20872500216, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ad01e8209da, moduleTitle=JAK抑制劑Olumiant聯(lián)合治療特應(yīng)性皮炎的III期試驗達到主要終點, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=6ad01e8209da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1993688, encodeId=c2e51993688b2, content=<a href='/topic/show?id=d1821023916' target=_blank style='color:#2F92EE;'>#JAK抑制劑Olumiant#</a>, objectTitle=禮來JAK抑制劑Olumiant治療系統(tǒng)性紅斑狼瘡的2期臨床試驗獲得成功, objectType=article, longId=145138, objectId=96a9145138b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96a9145138b2, replyNumber=0, likeNumber=92, createdTime=2019-02-12, rootId=0, userName=ms4657536712156177, userId=20872500216, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96a9145138b2, moduleTitle=禮來JAK抑制劑Olumiant治療系統(tǒng)性紅斑狼瘡的2期臨床試驗獲得成功, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=96a9145138b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
